143 related articles for article (PubMed ID: 10235027)
1. [Secondary debulking after dose-intensified chemotherapy of ovarian carcinoma].
Meier W; Gropp M; Burges A; Hepp H
Praxis (Bern 1994); 1999 Mar; 88(12):519-25. PubMed ID: 10235027
[TBL] [Abstract][Full Text] [Related]
2. [Value of tumor-reductive secondary operation (interventional laparotomy) in ovarian cancer].
Meier W; Römisch M; Hepp H
Geburtshilfe Frauenheilkd; 1993 Dec; 53(12):860-5. PubMed ID: 8119569
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer.
Lawton FG; Redman CW; Luesley DM; Chan KK; Blackledge G
Obstet Gynecol; 1989 Jan; 73(1):61-5. PubMed ID: 2462202
[TBL] [Abstract][Full Text] [Related]
4. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
6. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
[TBL] [Abstract][Full Text] [Related]
7. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
[TBL] [Abstract][Full Text] [Related]
8. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
9. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment.
Onda T; Yoshikawa H; Yasugi T; Matsumoto K; Taketani Y
Jpn J Clin Oncol; 2010 Jan; 40(1):36-41. PubMed ID: 19820253
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
[TBL] [Abstract][Full Text] [Related]
11. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
[TBL] [Abstract][Full Text] [Related]
12. [Early debulking surgery after chemotherapy in advanced cancer of the ovary].
de Gramont A; Pigné A; Louvet C; Sezeur A; Marpeau L; Vaillant JC; Cady J; Varette C; Demuynck B; Couturier JY; Lagadec B; Milliez J; Barrat J; Krulik M
Ann Chir; 1997; 51(10):1069-76. PubMed ID: 10868028
[TBL] [Abstract][Full Text] [Related]
13. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
14. [Surgical therapy of ovarian carcinoma].
Sevelda P
Wien Med Wochenschr; 1996; 146(1-2):18-22. PubMed ID: 8835491
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Wimberger P; Lehmann N; Kimmig R; Burges A; Meier W; Du Bois A;
Gynecol Oncol; 2007 Jul; 106(1):69-74. PubMed ID: 17397910
[TBL] [Abstract][Full Text] [Related]
16. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
Scarabelli C; Gallo A; Carbone A
Gynecol Oncol; 2001 Dec; 83(3):504-12. PubMed ID: 11733963
[TBL] [Abstract][Full Text] [Related]
17. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
Zang R; Zhang Z; Cai S
Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
[TBL] [Abstract][Full Text] [Related]
18. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic strategy in the management of stage II-IV epithelial ovarian carcinoma.
Sun T; Feng Y; Zhu Y; Zheng Y
Chin Med J (Engl); 2000 Jul; 113(7):625-7. PubMed ID: 11776033
[TBL] [Abstract][Full Text] [Related]
20. Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients.
Tsolakidis D; Amant F; Leunen K; Cadron I; Neven P; Vergote I
Eur J Cancer; 2011 Jan; 47(2):191-8. PubMed ID: 20880697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
